Reversible Effect of Falling Ventilatory Drive in Drive-dependent OSA

Launched by BRIGHAM AND WOMEN'S HOSPITAL · Oct 16, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating a new approach to treating a specific type of obstructive sleep apnea (OSA) called drive-dependent OSA. OSA is a common sleep disorder that can lead to serious health issues, including problems with the heart, brain, and overall quality of life. In this trial, researchers want to see if giving small amounts of carbon dioxide (CO2) at certain times during sleep can help maintain breathing and prevent OSA events in people who have this drive-dependent form of the condition.

To participate in this study, individuals must be diagnosed with OSA or have symptoms suggesting they might have it, such as snoring or excessive daytime sleepiness. Participants will need to stop using their regular OSA treatments for a short period before each study visit. However, those who drive for work or operate heavy machinery won’t need to stop their treatment. The study is open to people aged 16 to 80, regardless of gender. Participants can expect to undergo several tests during the trial, which will help researchers learn more about how CO2 can affect breathing during sleep. It's important to note that some people with certain medical conditions or allergies may not be eligible to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed OSA (AHI≥15 events/h reported in a PSG performed within 1 year) or Suspected OSA (snoring, sleepiness, witnessed apneas, other clinical symptoms)
• • Use of CPAP or other therapies is acceptable; individuals will be asked to withhold treatment for 3 days before each study visit. Individuals who are occupational drivers or operate heavy machinery will not be asked to withhold treatment.
• Exclusion Criteria:
• • Any unstable medical conditions
• • Conditions that could meaningfully raise the cardiovascular risks of brief low-dose hypercapnic-hypoxic inspired gas mixture: heart failure (LVEF\<45% if known), recent cardiovascular event (\<12 mo), recent cerebrovascular event (\<12 mo)\*
• • Medications known to depress ventilatory drive (e.g. opioids, barbiturates)
• • Conditions likely to increase arousability from sleep: insomnia
• • Other sleep disorders that may complicate establishment of sleep: periodic limb movements (periodic limb movement arousal index \> 10/hr), narcolepsy, or parasomnias
• • For intramuscular electrodes and catheter: allergy to lidocaine
• • Highly-sensitive gag reflex. Patients with a self-reported 'highly-sensitive gag reflex', including an affirmative response to 'Do you sometimes gag when brushing your teeth?', will not take part in the physiology studies given the placement of an esophageal catheter
• • For intramuscular electrodes: use of aspirin or other oral anti-platelets / anti-coagulants
• • For oronasal mask: severe claustrophobia
• • Pregnancy or nursing
• • We do not intend to exclude patients with controlled cardiovascular disease (hypertension of any severity, arrhythmias, stents) common in the OSA patient population. The transient gas mixture interventions are mild, short-lived, and act to slow the spontaneous recovery of blood gas levels to prevent cyclic upper airway obstruction as opposed to exacerbating them. Control of breathing studies commonly increase inspired CO2/reduce inspired oxygen (using higher concentrations via rebreathing tests for longer durations) in patients with a range of comorbidities including heart failure. The level of hypercapnic-hypoxia used is equivalent to taking slightly smaller breaths (by about a third, for the standard dose gas mixture 2%CO2/18.5%O2) for several breaths, or skipping a breath (for the highest dose gas mixture 6%CO2/14%O2), physiological changes that typically cause no noticeable oxygen desaturation, and are minimal compared with the effects of the larger ventilation reduction that accompanies OSA.